Share buy-back programs

Stock dividends, compensation plans & reducing issued capital

Buy-back programs

It is necessary for DSM to undertake regular share buy-back programs to cover its commitment to shareholders wishing to receive their dividend in the form of ordinary shares, as well as to fulfill its obligations under share-based compensation plans.

DSM obtains approval for the company to repurchase its own shares each year at the Annual General Meeting of Shareholders. Each year we also obtain approval to reduce the company's issued capital by cancellation of its shares up to a maximum of the number that is, or will be bought by, the company.

Current program

On 16 March 2021 DSM announced it intended to repurchase 800,000 ordinary shares starting 3 May 2021. This is to cover commitments for the final stock dividend 2020 and is equivalent to approximately €113 million based on the closing price of the DSM ordinary share on Euronext Amsterdam on 15 March 2021.

In accordance with regulations DSM informs the market about progress made in the execution of the buy-back program with weekly press releases. Similarly this spreadsheet breaking down the daily transaction details will be updated weekly throughout the course of the program.

Recent programs

Aug 2020

DSM repurchased a total of 200,000 shares for a combined consideration of €26.0m in accordance with the repurchase program announced on 7 August 2020.

Mar 2020

DSM repurchased a total of 1,400,000 shares for a combined consideration of €137.8m in accordance with the repurchase program announced on 2 March 20201.

Apr 2019 - Feb 2020

DSM repurchased a total of 9,238,971 shares for a combined consideration of €1.01bn in accordance with the repurchase program announced on 14 March 20191, 2

Aug - Oct 2018

DSM repurchased a total of 1,100,000 shares for a combined consideration of €98.9m in accordance with the repurchase program announced on 13 August 2018.

Mar - Apr & May - Jun 2018

DSM repurchased a total of 1,600,000 shares for a combined consideration of €136.7m in accordance with the repurchase program announced on 19 March 2018.

Aug - Nov 2017

DSM repurchased a total of 1,600,000 shares for a combined consideration of €109.3m in accordance with the repurchase program announced on 14 August 2017.

Mar - Jul 2017

DSM repurchased a total of 2,900,000 shares for a combined consideration of €187.2m in accordance with the repurchase program announced on 13 March 2017. 

Nov - Dec 2016

DSM repurchased a total of 1,700,000 shares for a combined consideration of €96.0m in accordance with the repurchase program announced on 4 November 2016.

Feb - Jul 2016

DSM repurchased a total of 3,500,000 shares for a combined consideration of €176.8m in accordance with the repurchase program announced on 22 February 2016.

May - Jul 2015

DSM repurchased a total of 2,300,000 shares for a combined consideration of €122.5m in accordance with the repurchase program announced on 14 May 2015.

1) Given Covid-19 and the acquisition of Erber Group, DSM canceled the remainder of the €1 billion share buy-back program in June 2020 having repurchased 6,638,971 shares during 2019 (5.4m shares/€600m) and January - February 2020 for a total of €745 million.

2) On 29 April 2021 DSM announced that it has cancelled 6.6m ordinary shares, thereby concluding the reduction in share capital following the share buyback program executed in the period 1 April 2019 to February 2020. 6,638,971 ordinary shares held in treasury since the execution of the share buyback program have been cancelled. The total number of issued shares is therefore reduced to 218,826,029 (previously 225,465,000), consisting of 174,786,029 ordinary shares and 44,040,000 cumulative preference shares A. 

Statement pursuant to art. 5:25a of the Dutch Financial Supervision Act

DSM declares that the Netherlands is its "Home Member State", as required by article 5:25a (2) of the Dutch Financial Supervision Act. This article obliges all listed companies to publicly announce which country is their "home member state" (as referred to in article 5:25a(1) sub c of the Dutch Financial Supervision Act) for purposes of regulation of their disclosure obligations under the EU Transparency Directive. Pursuant to section 5:25a of the Dutch Financial Supervision Act, Royal DSM has notified the Dutch Authority for the Financial Markets (AFM).

Read more

This site uses cookies to optimize your user experience.

Read more